Pulmatrix (NASDAQ: PULM) Investor Presentation

October 8, 2018 admin Healthcare, Investor Presentations Comments Off on Pulmatrix (NASDAQ: PULM) Investor Presentation

Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018

Pulmatrix Corporate Overview (2018.08) – final for website

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.




Related Articles

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin CEO Interview, Healthcare Comments Off on BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Healthcare

CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA

July 29, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA

VANCOUVER, Washington, Jul 25, 2019– – FDA face-to-face meeting granted to discuss pivotal monotherapy trial – Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. […]